Nocturne Acquisition in an 8-K said it has further postponed a shareholder vote on its proposed merger with Cognos Therapeutics. This is the fourth time the SPAC has rescheduled the vote, which is now set for April 2 at 9 a.m. Eastern.
The SPAC initially called a Jan. 30 meeting for shareholders to vote on the proposed merger , but that vote was pushed to Feb. 6, then delayed again so Nocturne could continue to solicit proxies.
Cognos specializes in drug delivery devices for brain and spinal cancers, neurodegenerative disorders (such as Alzheimer’s and Parkinson’s disease), epilepsy, and stroke.
Nocturne raised $100 million in a March 2021 IPO with plans at that time to focus on targets bringing to market disruptive technologies in the blockchain/crypto and artificial intelligence technology sectors. Redemptions in the nearly three years since had reduced the trust to about $20 million as of December. Read more.
